title: A prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase.
abstract: BACKGROUND
  Different doses of human chorionic gonadotropin (hCG) have been used in various in vitro fertilization (IVF) treatment protocols to achieve final oocyte maturation. There is as yet no agreement on the optimum dose required.
  
  
  OBJECTIVE
  The objective of this study was to compare the effectiveness of 250 and 500 microg recombinant hCG (r-hCG), which represented the lower and upper limits of the dose range, in inducing final oocyte maturation during IVF and intracytoplasmic sperm injection cycles.
  
  
  METHODS
  This was a prospective, randomized, double-blind study.
  
  
  METHODS
  This study was performed at an IVF clinic in a teaching hospital.
  
  
  METHODS
  Sixty patients with an indication for intracytoplasmic sperm injection were studied.
  
  
  METHODS
  The treatment dose used was 250 or 500 microg r-hCG.
  
  
  METHODS
  The percentage of metaphase II oocytes retrieved per patient, as an indicator of oocyte maturation, and the hormone profiles of the treatment cycle starting from the day of hCG up to hCG+10 d were the main outcome measures.
  
  
  RESULTS
  The percentage of metaphase II oocytes was similar in the two groups (89.3% vs. 86.0%; P = 0.326) despite higher serum and follicular fluid hCG levels on hCG+2 and hCG+4 d, as was the follicular fluid to serum hCG ratio in the 500-microg r-hCG group. Serum estradiol and progesterone levels were comparable initially, but became significantly higher in the 500-microg r-hCG group on hCG+10 d.
  
  
  CONCLUSIONS
  The two doses of r-hCG were equally effective in inducing final oocyte maturation. It remains unclear whether the higher midluteal estradiol and progesterone levels in the 500-microg r-hCG group confer any benefit.
authors.affiliation: Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China. cwcchan@graduate.hku.hk
authors.forename: Carina C W
authors.initials: CC
authors.lastname: Chan
authors.forename: Ernest H Y
authors.initials: EH
authors.lastname: Ng
authors.forename: O S
authors.initials: OS
authors.lastname: Tang
authors.forename: William S B
authors.initials: WS
authors.lastname: Yeung
authors.forename: Estella Y L
authors.initials: EY
authors.lastname: Lau
authors.forename: P C
authors.initials: PC
authors.lastname: Ho
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008183:Luteal Phase / Q000097:blood / Q000502:physiology*; D009865:Oocytes / Q000187:drug effects* / Q000502:physiology; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D011374:Progesterone; D004958:Estradiol